Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China
Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer / Additional indication based on data from the pivotal Phase III ARASENS trial
Source: bayer.com